Midatechpharma Security Rating

Midatech is a world leader in the design, synthesis and manufacture of biocompatible gold nanoparticles (GNPs) with a core focus on therapeutics for diabetes and cancer. Midatech has a strong pipeline of product candidates in clinical and pre-clinical development for the treatment of diabetes and various cancers. In 2012, Midatech established MidaSol Therapeutics LP, a strategic joint venture with MonoSol Rx LLC to focus on the development and commercialization, via partnering or licensing, of products primarily for the treatment of diabetes. MidaSol’s lead product, Midaform™ Insulin PharmFilm, is a unique product for the oral delivery of insulin in diabetic patients and will enter Phase II clinical studies in 2014. These technologies are also being evaluated in the diabetes area by a major US pharmaceutical company. Midatech’s unique GNP technology enables the administration and targeted delivery of therapeutic compounds to specific cells and tissues. Multiple drug molecules can be attached to one of its GNPs allowing multivalent drug or multi-drug delivery. The size of the GNPs potentially also enables drug delivery via a variety of different routes of administration, such as oral, parental, transdermal, mucosal, intradermal, transbuccal, sublingual or intranasal/inhalation. Midatech has exclusive world-wide IP for the technology covering design, manufacture and application of nanoparticles in therapeutic and diagnostic pharmaceutical areas as well as in other industries. In 2014, Midatech Pharma acquired Q Chip, now Midatech Pharma Wales to support novel delivery platforms and product developments in cancer, diabetes and ophthalmology. Q Chip has developed a complementary technology and products that allow sustained release of substances over extended periods of time and will provide a platform to incorporate Midatech's gold nanoparticle (GNP) compounds for sustained and extended release.